Form 4: Neurocrine Biosciences Officer's RSU Vesting & Tax Withholding

Neurocrine Biosciences Chief Corporate Affairs Officer David W. Boyer acquired shares through RSU vesting and had shares withheld for tax obligations.

Summary

• David W. Boyer, Chief Corporate Affairs Officer at Neurocrine Biosciences Inc. (NBIX), acquired 2,096 shares of common stock on January 31, 2026, through the vesting of Restricted Stock Units (RSUs).
• Concurrently, 1,189 shares were withheld by the company at a price of $136.06 per share to cover tax withholding requirements related to the RSU vesting.
• No shares were sold by Mr. Boyer in this transaction.
• Following these transactions, Mr. Boyer directly beneficially owns 4,713 shares of common stock.
• The RSU award, granted on January 31, 2022, fully vested with this final tranche of 2,096 shares on January 31, 2026.
• Beneficial ownership also includes 241 shares purchased through the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan on February 28, 2025, and August 29, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and a pre-scheduled vesting, which aligns executive interests with the company's long-term performance.

Positives

• Officer David W. Boyer converted 2,096 Restricted Stock Units into common stock, resulting in a net increase of 907 directly beneficially owned shares after tax withholding, aligning his interests with long-term shareholder value.

Negatives

• 1,189 shares were withheld by the company to satisfy tax obligations, reducing the net number of shares received by the officer from the RSU vesting.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax withholding are standard compensation practices for executives in the biotechnology and pharmaceutical industries, aligning executive incentives with long-term company performance.

Comparison to Industry Standards

• The RSU vesting schedule, typically over several years, is a common practice in the biotechnology sector to retain key talent and incentivize long-term performance, comparable to practices at companies like Amgen or Gilead Sciences.
• The withholding of shares for tax purposes upon RSU vesting is a standard, non-discretionary event, consistent with compensation practices across publicly traded companies in the U.S.

Stakeholder Impact

• Shareholders: The transaction reflects a routine compensation event for a key executive, aligning management's interests with shareholder value through equity ownership.
• Employees: The mention of the Employee Stock Purchase Plan (ESPP) highlights a broader employee benefit program, which can contribute to employee retention and engagement.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled RSU vesting and tax withholding for an executive. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It primarily confirms ongoing executive equity compensation practices.

Keywords

Neurocrine Biosciences, NBIX, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, David W. Boyer, Chief Corporate Affairs Officer, Stock Purchase Plan, Employee Stock Ownership